Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
- First Posted Date
- 2025-07-06
- Last Posted Date
- 2025-07-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11
- Registration Number
- NCT07052682
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Southern California Research Center, Coronado, California, United States
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
Not Applicable
Not yet recruiting
- Conditions
- Dengue Fever
- Interventions
- Biological: Tetravalent Dengue Vaccine (TDV)
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 496
- Registration Number
- NCT07047521
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
Not yet recruiting
- Conditions
- Colorectal Cancer
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT07035886
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Phase 3
Not yet recruiting
- Conditions
- Multiple MyelomaSecondary Immunodeficiency
- Interventions
- Biological: IGI, 10%
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 183
- Registration Number
- NCT06980480
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Phase 3
Not yet recruiting
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Placebo to match zasocitinibDrug: Placebo to match deucravacitinib
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT06973291
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 13
- Registration Number
- NCT06973304
- Locations
- 🇨🇳
Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
🇨🇳Beijing Tsinghua Changgung Hospital, Changping, Beijing, China
🇨🇳Peking Union Medical College Hospital, Dongcheng, Beijing, China
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 347
- Registration Number
- NCT06963827
Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA
- Conditions
- Primary Immunodeficiency Diseases (PIDD)
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Takeda
- Registration Number
- NCT06955793
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT06952699
- Locations
- 🇺🇸
Takeda Site 14, Redwood City, California, United States
🇺🇸Takeda Site 10, Santa Ana, California, United States
🇺🇸Takeda Site 1, Colorado Springs, Colorado, United States
A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Phase 3
Not yet recruiting
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06948318